Publication at Third Faculty of Medicine |
2013
Abstract
Ovarian cancer in Czech Republic takes first place in mortality among gynecological malignant tumours. In most cases it is diagnosed in advanced stages.
Initial treatment is based on combination of radical surgery and adjuvant chemotherapy. In more than two thirds of cases ovarian cancer relapses sooner or later, very often without a chance to cure the patient.
Unsatisfying result of standard treatment is reason of looking for more effective procedures. Targeted the- rapy is subject of research in last years.
Positive effect of bevacizumab has been proved. Through inhibition of angiogenesis it leads to prolonging of interval to cancer progression